Pharmacoeconomic comparison of Helicobacter pylori eradication regimens

SANCAR M., Izzettin F. V., APIKOGLU-RABUS S., BESISIK F., TOZUN N., DULGER G.

PHARMACY WORLD & SCIENCE, vol.28, no.4, pp.207-214, 2006 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 28 Issue: 4
  • Publication Date: 2006
  • Doi Number: 10.1007/s11096-006-9021-y
  • Journal Name: PHARMACY WORLD & SCIENCE
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.207-214
  • Keywords: cost-effectiveness, eradication regimens, gastritis, Helicobacter pylori, peptic ulcer, pharmacoeconomics, COST-EFFECTIVENESS ANALYSIS, PEPTIC-ULCER DISEASE, DUODENAL-ULCER, ANTIBIOTIC-RESISTANCE, BISMUTH SUBCITRATE, TRIPLE THERAPY, INFECTION, OMEPRAZOLE, MANAGEMENT, AMOXICILLIN
  • Bezmialem Vakıf University Affiliated: No

Abstract

Background Helicobacter pylori is the most important etiologic agent for development of peptic ulcer, chronic gastritis and gastric carcinomas. It is now well established that H. pylori eradication treatment is more cost-effective than acid suppressing therapies alone for the treatment of peptic ulcer disease. However, the comparative cost-effectiveness of various H. pylori eradication regimens is still not clear.